Bio-Techne Corp - TECH STOCK NEWS

Bio-Techne (NASDAQ: TECH) announced advancements in its RNAscope technology for biomarker detection and pathology laboratory workflow improvements, to be presented at the 2025 USCAP Annual Meeting in Boston (March 22-27). The company's Advanced Cell Diagnostics brand will showcase the technology at booth #222.

During the 'RNAscope: Lightning Lunch and Learn' session on March 25, four leading pathologists will present their research:

• Dr. Rohit Mehra on TRIM63 mRNA as a marker in renal cell carcinoma
• Dr. Vikram Deshpande on albumin mRNA for liver tumors
• Dr. Brooke Howitt on point mutation detection in gynecologic tumors
• Dr. Gregory Bean on mRNA detection from CRTC1/3::MAML2 translocations

The presentations will demonstrate RNAscope's potential to improve performance over existing methods and reduce time to results in detecting clinically relevant biomarkers, including secreted proteins, point mutations, and chromosomal translocations.

Bio-Techne (NASDAQ: TECH) has launched Leo™, a next-generation Simple Western™ system that significantly enhances protein analysis capabilities. The system can process up to 100 samples in a single 3-hour run, delivering 4x higher throughput than the Jess™ system and 5x faster processing than Sally Sue™ and Peggy Sue™ systems.

Leo features enhanced Compass Software with advanced analysis capabilities and improved 21 CFR Part 11 Compliance support. The system offers experimental size, precision, and reproducibility suitable for regulatory submissions. Beta testers have praised Leo's robust performance and versatility across applications including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control, and recombinant protein expression.

Bio-Techne (NASDAQ: TECH) has announced the launch of the AmplideX® Nanopore Carrier Plus Kit, a genetic panel and analysis software for carrier screening research, developed in collaboration with Oxford Nanopore Technologies. The innovative kit addresses challenges in analyzing genes that are difficult to assess using conventional short-read sequencing.

The 11-gene panel includes the most prevalent recommended genes that conventional methods struggle to detect accurately. By combining AmplideX long-range PCR and nanopore long reads, the kit provides a streamlined, single-workflow solution for comprehensive sequencing data, replacing the need for multiple testing technologies like MLPA, Sanger sequencing, qPCR, and long-range PCR.

The panel targets key genes including CFTR, CYP21A2, F8 inversions, FMR1, GBA, HBA1, HBA2, HBB, SMN1, SMN2, and TNXB. This development aligns with the American College of Medical Genetics and Genomics' 2021 updated recommendations for carrier screening.

Bio-Techne (NASDAQ: TECH) has launched an expanded menu of RNAscope™ in situ hybridization probes for human and mouse transcriptome research. This expansion aims to advance spatial biology research and the development of next-generation therapeutics and diagnostics. The Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across more than 450 species. RNAscope is noted for its spatial precision, sensitivity, and specificity, providing a single-cell view of disease pathology and therapeutic response.

This expansion allows customers to accelerate the validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available on bio-techne.com, customers can easily select RNAscope probes along with R&D Systems antibodies to study changes in cell phenotypes and functional states. The probes come in manual and automated formats, including compatibility with the Lunaphore COMET™ system, enabling seamless advancement from late discovery to translational research or clinical assay development.

Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, emphasized that the expanded portfolio, with over 12,000 citations in clinical and translational research, empowers customers to accelerate biomarker validation and improve lives.

Bio-Techne (NASDAQ: TECH) has announced the release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, aimed at supporting immune cell- and stem cell-based therapy development and manufacturing. The system offers significant advantages over traditional lentivirus-based engineering methods, featuring a hyperactive enzyme capable of delivering multiple genes simultaneously while maintaining high editing efficiency.

The TcBuster system eliminates the need for viral clearance methods, reducing time to market and costs for cell therapy developers. It's compatible with various cell types, including immune cells and stem cells, and can be used for applications like autologous CAR-T, TCR manufacturing, allogeneic NK therapies, and engineering bioprocessing cell lines. Bio-Techne provides both RUO & GMP grade reagents with closed-system manufacturing options.

Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2024. The dividend will be paid on February 28, 2025, to shareholders of record as of February 17, 2025.

The company, a global life sciences organization providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of approximately $1.2 billion in fiscal 2024. Bio-Techne employs around 3,100 people worldwide and maintains a portfolio of thousands of products supporting scientific investigations, biological processes research, drug discovery, and clinical testing.

Bio-Techne (NASDAQ: TECH) reported strong Q2 FY2025 financial results with 9% organic revenue growth to $297.0 million. The company's GAAP EPS increased to $0.22 from $0.17 year-over-year, while adjusted EPS rose to $0.42 from $0.40.

The Protein Sciences segment achieved 8% organic growth (7% reported) to $211.6 million, driven by improving biopharma end-market conditions and momentum in cell and gene therapy workflow solutions. The segment's operating margin improved to 41.2% from 40.3%.

The Diagnostics and Spatial Biology segment demonstrated strong performance with 12% organic growth to $84.1 million, though operating margin decreased to 3.9% from 6.0% due to re-instatement of incentive compensation accruals.

Overall adjusted operating margin remained stable at 30.1%, with volume leverage offsetting compensation accrual impacts.

Bio-Techne (NASDAQ: TECH) has appointed Dr. Amy E. Herr to its Board of Directors, effective February 1, 2025. Dr. Herr, who will serve on the Board's Science & Technology Committee, is currently a Chancellor's Professor of Bioengineering at UC Berkeley and Vice President of the Chan Zuckerberg Biohub Network.

Dr. Herr brings significant experience in bioengineering and leadership roles, including serving as Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub and on the National Advisory Council for Biomedical Imaging and Bioengineering. Notably, she was a co-founder of Zephyrus Biosciences, which Bio-Techne acquired in 2016.

This appointment completes a two-year board succession process, with Dr. Herr succeeding Dr. Roeland Nusse, who will retire later in 2025. The company's leadership highlighted her deep biological and engineering expertise as particularly valuable for Bio-Techne's strategic direction and growth in proteomic analytical instruments.

Bio-Techne (NASDAQ: TECH) has announced it will host a conference call and webcast on February 5, 2025, at 8:00 a.m. CST to discuss its second quarter fiscal 2025 financial results. Participants can join via phone by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) using Conference ID 13751305. The event will also be accessible through a webcast on the company's investor relations website.

For those unable to attend live, a recorded rebroadcast will be available from 11:00 a.m. CST on February 5 until 11:00 p.m. CST on March 5, 2025. The replay can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).